Valuation: Geron Corporation

Market Cap 790M 696M 659M 595M 1.12B 75.77B 1.14B 7.89B 3.04B 38.74B 2.97B 2.9B 124B P/E 2026 *
-29.3x
P/E 2027 * 18.1x
Enterprise Value 790M 696M 659M 595M 1.12B 75.77B 1.14B 7.89B 3.04B 38.74B 2.97B 2.9B 124B EV / Sales 2026 *
3.34x
EV / Sales 2027 * 2.31x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.81%
1 week-0.81%
1 month-17.45%
3 months-3.91%
6 months-17.45%
Current year-6.82%
1 week 1.21
Extreme 1.21
1.27
1 month 1.2
Extreme 1.2
1.62
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/6/26 Free

Director

6,103 0.0010%
20/5/26 Free

Director

220,000 0.0343%
20/5/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%-0.81%-10.22%-41.98% 790M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.09%+1.34%+27.91%+81.16% 60.14B
-0.73%+0.32%+6.96%+35.98% 48.15B
-0.05%+0.37%+41.54%+36.65% 44.25B
+0.38%+7.61%+339.53%+641.55% 43.99B
+0.18%+0.26%+7.41%+103.45% 41.61B
-0.67%+0.17%+7.60%+46.37% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-1.29%-3.55%-20.74%+352.04% 24.93B
Average +0.65%+0.84%+48.61%+137.22% 39.76B
Weighted average by Cap. +1.03%+1.52%+59.24%+147.32%

Financials

2026 *2027 *
Net sales 236M 208M 197M 178M 335M 22.65B 340M 2.36B 908M 11.58B 887M 868M 37.13B 342M 301M 285M 258M 485M 32.79B 492M 3.41B 1.31B 16.76B 1.28B 1.26B 53.74B
Net income -27.18M -23.94M -22.68M -20.47M -38.59M -2.61B -39.09M -271M -104M -1.33B -102M -99.84M -4.27B 50.14M 44.16M 41.84M 37.77M 71.19M 4.81B 72.11M 501M 193M 2.46B 188M 184M 7.88B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
30/09/26 USD 1.230 -0.81% 9,443,026
29/09/26 USD 1.240 -0.80% 12,498,969
28/09/26 USD 1.250 -0.79% 9,974,090
25/09/26 USD 1.260 -.--% 10,302,825
24/09/26 USD 1.260 +1.61% 6,413,404
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.230USD
Average target price
4.250USD
Spread / Average Target
+245.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock